Skip to content
Triangle logo TriangleGet started
← Study library

NCT03082534 · REGISTRY CONDITION SEARCH

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2026-10-01

This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC. There will be four patient cohorts, including a PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve arm (Cohort 1), a PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve arm (Cohort 2), a PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory arm (Cohort 3), and a cutaneous HNSCC arm (Cohort 4). A total of 83 patients (33 in Cohort 1, 25 in Cohort 2, 15 in Cohort 3, and 10 in Cohort 4) will be eligible to enroll. Patients will be enrolled at 4 sites: UC San Diego Moores Cancer Center, UC Los Angeles Jonsson Comprehensive Cancer Center, University of Michigan Comprehensive Cancer Center, and University of Washington Siteman Cancer Center.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Overall Survival

→

outcome · NOT POSTED

Duration of Response

→

outcome · NOT POSTED

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03

→

outcome · NOT POSTED

Correlative Analyses

→

outcome · NOT POSTED

Correlative Analyses

→

outcome · NOT POSTED

Correlative Analyses

→

outcome · NOT POSTED

Correlative Analyses

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: Patients must meet all of the inclusion criteria to participate in this study. 1. Ability to understand and the willingness to sign a written informed consent. 2. Histologically or cytologically proven squamous cell carcinoma of the head and neck (lip, oral cavity, oropharynx, larynx, hypopharynx, non-EBV related nasopharynx, sinonasal, cutaneous), not amenable to curative intent therapy. 3. Platinum-refractory disease, or ineligible/unfit for platinum-based therapy 4. Patients must have at least one measurable site of disease as defined by RECIST v.1.1, determined by investigator review 5. Age ≥ 18 years. 6. Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1. 7. Patient has adequate hematologic, hepatic and renal function 8. Female patient of childbearing potential has a negative serum or urine pregnancy within 72 hours prior to receiving the first dose of study medication. 9. Female patient of childbearing potential agrees to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. 10. Male patient with a partner of childbearing potential agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. Additional Inclusion Criterion for Cohort 1 (PD-1/PD-L1 Inhibitor-naïve, Cetuximab-naïve) and Cohort 2 (PD-1/PD-L1 Inhibitor-refractory, Cetuximab-naïve): 1\. Cetuximab-naïve patients may not have received cetuximab therapy in the recurrent/metastatic setting (treatment in curative setting permitted) Additional Inclusion Criterion for Cohorts 2 and 3 (PD-1/PD-L1 Inhibitor-refractory): 1\. PD-1/PD-L1 inhibitor-refractory patients must have documented disease progression after prior response to anti-PD-1/PD-L1 therapy (response defined as stable disease, partial or complete response) Additional Inclusion Criterion for Cohort 4 (Cutaneous HNSCC): 1\. Cutaneous HNSCC must not be amenable to local treatment modalities, including surgery and/or radiation. Exclusion Criteria: Patients meeting any of the exclusion criteria at baseline will be excluded from study participation. 1. Patient has salivary gland primary. 2. Patient is currently receiving or has received another investigational agent within 4 weeks prior to Day 1 of study. 3. Patient has received chemotherapy or radiotherapy within 4 weeks prior to Day 1 of study. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been radiated. 4. Patient has received a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or baseline) from adverse events due to a previously administered agents. 5. Patient has had major surgery or insufficient recovery from surgical-related trauma or wound healing within 14 days of Study Day 1. 6. Patient has had a prior Grade ≥ 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \> Grade 1. 7. Patient has had prior Grade 4 infusion reaction to cetuximab. 8. Patient has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 9. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. 10. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Notes: * Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within the past 2 years are not excluded. * Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 11. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\>10mg prednisone daily, or steroid equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab. 12. Patient has a known history of active TB (Baccillus Tuberculosis). 13. Patient has a known history of, or any evidence of active, non-infectious pneumonitis. 14. Patient has a known history of chronic interstitial lung disease. 15. Patient has an active infection requiring systemic therapy. 16. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 17. Patient has a known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 18. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial. 19. Patient has known active Hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known Human Immunodeficiency Virus (HIV) carrier (HIV 1/2 antibodies). 20. Patient has received a live vaccine within 30 days of study Day 1. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. Additional Exclusion Criterion for Cohorts 1 (PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve) and 4 (cutaneous): 1\. Patient has received any prior immunotherapy with inhibitors of PD-1 or PD-L1.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).
    intervention Names
    1. Drug: Pembrolizumab, Cetuximab
    label
    Cohort 1
    type
    EXPERIMENTAL
  2. description
    PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).
    intervention Names
    1. Drug: Pembrolizumab, Cetuximab
    label
    Cohort 2
    type
    EXPERIMENTAL
  3. description
    PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).
    intervention Names
    1. Drug: Pembrolizumab, Cetuximab
    label
    Cohort 3
    type
    EXPERIMENTAL
  4. description
    cutaneous HNSCC Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).
    intervention Names
    1. Drug: Pembrolizumab, Cetuximab
    label
    Cohort 4
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Cohort 1
    2. Cohort 2
    3. Cohort 3
    4. Cohort 4
    description
    Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection. Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR.
    name
    Pembrolizumab, Cetuximab
    other Names
    1. Keytruda®, Erbitux®
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
intervention Model Description
Open-label, non-randomized, multi-arm phase II trial of pembrolizumab combined with cetuximab for patients with recurrent/metastatic head and neck squamous cell carcinoma 1. Cohort 1 (PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve): clinical efficacy defined as overall response rate. 2. Cohort 2 (PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve): clinical efficacy defined as overall response rate. 3. Cohort 3 (PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory): clinical efficacy defined as overall response rate. 4. Cohort 4 (cutaneous HNSCC): clinical efficacy defined as overall response rate.
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
78
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Proportion of patients with partial or complete response in tumor burden as defined by RECIST
    measure
    Overall Response Rate
    time Frame
    6 months from the time of study enrollment
secondary Outcomes
  1. description
    No disease progression or death from any cause at 12 months from the time of study enrollment
    measure
    Progression Free Survival
    time Frame
    12 months from the time of study enrollment
  2. description
    Time from study enrollment to death from any cause
    measure
    Overall Survival
    time Frame
    From the time of study enrollment until the date of death from any cause or completion of study, whichever came first, assessed up to 36 months
  3. description
    Time from documentation of tumor response to disease progression
    measure
    Duration of Response
    time Frame
    Every 9 weeks from first on-treatment scan until disease progression or patient withdrawal from study or date of death from any cause, whichever came first, assessed up to 36 months
  4. description
    Description, grade (per CTCAE v4.03), seriousness and relatedness
    measure
    Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03
    time Frame
    Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months
  5. description
    Tumor tissue biomarkers correlated with outcome to pembrolizumab or cetuximab, such as PD-L1 expression, EGFR expression, p16 status, and immunophenotyping
    measure
    Correlative Analyses
    time Frame
    Tumor specimens (archival or new specimen) should be obtained within 42 days of screening
  6. description
    Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including T cell receptor (TCR) sequencing
    measure
    Correlative Analyses
    time Frame
    Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months
  7. description
    Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including Epstein-Barr virus plasma DNA titers
    measure
    Correlative Analyses
    time Frame
    Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months
  8. description
    Whole exome sequencing for neoantigen discovery
    measure
    Correlative Analyses
    time Frame
    Newly obtained tumor specimen within 42 days of screening (when feasible)
Full study description
brief Summary
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC. There will be four patient cohorts, including a PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve arm (Cohort 1), a PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve arm (Cohort 2), a PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory arm (Cohort 3), and a cutaneous HNSCC arm (Cohort 4). A total of 83 patients (33 in Cohort 1, 25 in Cohort 2, 15 in Cohort 3, and 10 in Cohort 4) will be eligible to enroll. Patients will be enrolled at 4 sites: UC San Diego Moores Cancer Center, UC Los Angeles Jonsson Comprehensive Cancer Center, University of Michigan Comprehensive Cancer Center, and University of Washington Siteman Cancer Center.
detailed Description
Primary Objectives: To determine the clinical efficacy of pembrolizumab combined with cetuximab for patients with R/M HNSCC. 1. Cohort 1 (PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve): clinical efficacy defined as overall response rate. 2. Cohort 2 (PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve): clinical efficacy defined as overall response rate. 3. Cohort 3 (PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory): clinical efficacy defined as overall response rate. 4. Cohort 4 (cutaneous HNSCC): clinical efficacy defined as overall response rate. Secondary Objectives: 1. To determine 12 month progression-free survival probability. 2. To determine overall survival. 3. To determine duration of response. 4. To assess safety and tolerability of pembrolizumab combined with cetuximab. 5. To evaluate the correlation between molecular markers and disease outcome.
Source references
references
  1. citation
    Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):883-892. doi: 10.1016/S1470-2045(21)00136-4. Epub 2021 May 11.
    pmid
    33989559
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-ed65b07fb707529eef6b84b3
      edge id
      nct-edge-31cdc9431985d3b87661
      requested nct id
      NCT03082534
      primary nct id
      NCT03082534
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      1830c3d19a70230dea5f3e3cbe92b87cf0999acbf0df384e771568752c5d65e9
      payload sha256
      7f90a6d41deea8fce73cf56b63b9478823292f9453f973adcc465dec38eadbfe
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-31cdc9431985d3b87661
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03082534
      occurrences
      1. context exact
        NCT03082534
        end
        11
        exact text
        NCT03082534
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-10-20/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      1830c3d19a70230dea5f3e3cbe92b87cf0999acbf0df384e771568752c5d65e9
      source json pointer
      /studies/106/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      89fe3881f6aee919c11671fb69aa410f1ba60d65e7978b9926e7ab5d72a1ded9
    2. release id
      ctgov-registry-ed65b07fb707529eef6b84b3
      edge id
      nct-edge-df01c1d204986b0acf6a
      requested nct id
      NCT03082534
      primary nct id
      NCT03082534
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      b7dd8c1db985216ab58159843a2af73e724013f8b33acf9bbf7794b20f9c88f8
      payload sha256
      6bc7a1fca92d984714c14d95aab649404fed71e34d772380be704b8a47d9079f
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-df01c1d204986b0acf6a
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03082534
      occurrences
      1. context exact
        NCT03082534
        end
        11
        exact text
        NCT03082534
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-10-20/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      b7dd8c1db985216ab58159843a2af73e724013f8b33acf9bbf7794b20f9c88f8
      source json pointer
      /studies/76/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      89fe3881f6aee919c11671fb69aa410f1ba60d65e7978b9926e7ab5d72a1ded9

    Preserved source evidence · Not medical advice